C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.
about
Disease monitoring in inflammatory bowel diseaseDoes long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.Therapeutic drug monitoring in patients with inflammatory bowel diseaseCan Dynamic Contrast-Enhanced MRI (DCE-MRI) and Diffusion-Weighted MRI (DW-MRI) Evaluate Inflammation Disease: A Preliminary Study of Crohn's DiseaseRole of biomarkers in the study and management of inflammatory bowel disease: a "nonsystematic" review.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis.Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel DiseaseInfliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab.Risk and management of intra-abdominal abscess in Crohn's disease treated with infliximab.Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn's disease in patients treated with anti-TNF treatment.Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease.
P2860
Q26777553-680ACEAC-5334-4330-89CE-BF3B9C78DE8DQ33606172-E369F09D-4214-4F80-B03E-069321516B6FQ35140715-14FACC91-2F81-48F6-A99F-128CA9DE70B1Q37206657-97C8571F-CA99-4A6D-8809-156F24E3869AQ38249415-D6905F1E-F671-49AE-93C1-564AFA580CB2Q38365049-394E8767-7933-4433-9DD5-893BAD32730CQ38435506-B4111B94-6583-4D2D-8C77-3C9C34E8567CQ38619950-53BE7EE9-F3C8-4069-B75B-DD48E4E2AD79Q38620415-179F985F-6B75-4E89-879D-D49D02EF8C58Q38652276-F69BED3B-870D-46B0-93FE-87336C3658AAQ38695300-46067D07-6284-4123-87FB-EAA558585DD5Q38695700-9CBDAC04-48E5-466D-97B7-82B3CAE48BB5Q38789642-3DCC1785-B3FC-4294-8480-96B27CF7FFD9Q38822920-2A438359-C997-47A4-A755-870F25E88E0FQ38856947-D45D8BA9-8518-4B00-912B-82154FB1F90AQ38919270-680B47D4-0EA6-4FDC-B2AC-BA554560814BQ38986222-AE924B2C-3D11-4539-81BC-42A4B05643D3Q39152159-C4F719A5-C43B-4A4A-A4EB-F422E3C6BA84Q43988900-DCA93069-4297-4D2D-B034-5BA434A79FF6Q47361114-486FB612-AD3D-48D7-B581-2D407F931D5FQ47422402-D4D47C80-F7FA-4F9C-91AF-4C5B5F9B3CDDQ50689278-A188F952-3C35-4C44-AFA2-1BB6C32482DEQ53043853-8512EA48-3EA6-494D-87B1-571218ADD409Q53718821-87E92561-550B-4262-9676-FFD2A01AF771
P2860
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
C-reactive protein is an indic ...... patients with Crohn's disease.
@en
C-reactive protein is an indic ...... patients with Crohn's disease.
@nl
type
label
C-reactive protein is an indic ...... patients with Crohn's disease.
@en
C-reactive protein is an indic ...... patients with Crohn's disease.
@nl
prefLabel
C-reactive protein is an indic ...... patients with Crohn's disease.
@en
C-reactive protein is an indic ...... patients with Crohn's disease.
@nl
P2093
P2860
P1476
C-reactive protein is an indic ...... patients with Crohn's disease.
@en
P2093
Hiroaki Ito
Ichiro Hirata
Kazuhiko Kawakami
Kenta Motegi
Mamoru Watanabe
Masakazu Takazoe
Noriko Sato
Satoshi Motoya
Shinji Tanaka
Takayuki Matsumoto
P2860
P304
P356
10.1007/S00535-013-0807-0
P577
2013-04-20T00:00:00Z